6 news items
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
IFRX
6 Jun 24
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
IFRX
9 May 24
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
fllogek
IFRX
24 Apr 24
pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One
- Prev
- 1
- Next